In Argentina today, women have access to mammograms and breast cancer screening through the public healthcare system at no direct cost, a stark contrast to the United States and many other countries where similar services often require expensive insurance copays or out‑of‑pocket payments.
Under Argentina’s National Program for Control of Breast Cancer, preventive services such as breast exams, diagnostic imaging and mammography are part of a nation‑wide effort to detect cancer early and reduce mortality, backed by quality control, disease monitoring and widespread coverage.
A 2021 study published in the Journal of Cancer Education examined how Argentina’s public system works to address barriers and delays in care, focusing on the time from when symptoms first appear to the first medical consult.
This research highlights that despite challenges — including delays in diagnosis and some cases still being detected at advanced stages — Argentina’s universal system provides free access to early detection and screening services for all women, without the kind of direct charges common in U.S. healthcare.
In the U.S., on the other hand, many women face significant costs for genetic testing or screening procedures, and even those with insurance can end up paying hundreds or thousands of dollars out of pocket, especially for specialized tests like BRCA gene analysis.
This difference in access and cost between a developing country and the world’s richest country underscores a broader point: while no system is perfect, Argentina’s public healthcare infrastructure reduces financial barriers to early cancer detection in ways that remain out of reach for many women in privately funded systems.
The prerequisites to receive the advanced BRCA test free of charge in Argentina are:
• If an immediate family member had breast or ovarian cancer.
• If three or more members of the extended family had breast or ovarian cancer.
• If any male individual in the immediate or extended family had breast cancer.
The Growth of Preventative Genetic Testing
In 2013 Hollywood actress Angelina Jolie made history when she published an op-ed in the New York Times revealing that she had a preventative double mastectomy and subsequent reconstructive surgery after testing positive for a BRCA gene mutation associated with high rates of breast cancer.
The mainstream press hailed Jolie’s revelation as a brave move that helped to bring awareness to breast and ovarian cancer gene testing and preventative mastectomies.
Others saw it as a publicity stunt that served to boost the stock of Myriad Genetics, the company that has owned the patents for the BRCA1 and BRCA2 gene sequences since the mid 1990s.
Ownership of a gene patent entitles a company to prevent other entities from testing or researching the gene, or to charge royalty fees for its use.
In the United States, a Myriad Genetics BRCA diagnostic test costs US$3,000-4,000. Even those with insurance will most likely have out of pocket expenses of $300 upward to get the test.
According to the U.S. National Cancer Institute less than 5% of women have the BRCA genetic mutation that can lead to the development of breast or ovarian cancer, but those women have a 60-80% chance of developing breast cancer.
Nine to twelve percent of women in the general population will develop breast cancer in their lifetime.
Argentina has the second highest rates mortality rate for breast cancer in Latin America, highlighting why this diagnostic test is so important.
BRCA Testing & Costs via the Argentine Health System
In Argentina, women who are residents or covered through the national network via an obra social who are considered at risk for the gene mutation can access BRCA genetic testing without a direct fee, following standard risk‑based criteria and genetic counseling.
For foreign women traveling to Argentina seeking BRCA testing, the practical option is to go through private medical providers.
The current private cost in Argentina (based on clinics and labs offering genetic panels) for a basic BRCA1/BRCA2 only panel is about US$ 200 – US$ 500.
A more comprehensive hereditary cancer gene panel (beyond BRCA1/2) can cost around US$ 800 – US$ 1,500.
Prices vary depending on the laboratory, the specific genes tested, and how many individual markers are included in the panel.
Even at the higher end, these private costs are significantly lower than out‑of‑pocket rates in the U.S., where BRCA testing can run US$ 3,000–US$ 6,000 or more without insurance coverage.
After Jolie’s mastectomy announcement, requests for the test increased at hospitals in Argentina (Spanish).
Women visiting Argentina who would like to get the test should plan to be in Argentina for several weeks to get signed up, go through genetic counseling that precludes testing and get an appointment.
Medical Tourism for Gene Testing?
Argentina already welcomes thousands of medical tourists annually for a range of services — from dental work and cosmetic procedures to specialized diagnostics.
Foreign women who are interested in genetic testing for cancer and don’t have it covered by insurance at home may consider taking a vacation and essentially paying for their trip by taking advantage of free or lower cost testing in Argentina.
Residents who wish to get the test via the public health system need to show up early in the morning at Hospital Rivadavia’s National Genetic Center to request an appointment and get the ball rolling.
Another alternative for those staying in Argentina a while is to get on an insurance plan, which will have co-pays that are reasonable for young people and get quite expensive (for Argentina) after 65.
Preventative Mastectomy and Reconstructive Surgery
While some women who test positive, as Jolie did, may opt for prophylactic mastectomy, the procedure is not common in Argentina or anywhere else.
Women diagnosed as carriers of the gene here will most likely be given instructions to modify their lifestyle and be given over the counter medications including chemopreventive therapy.
With the high number of skilled plastic surgeons in Argentina, carriers of the gene mutation certainly have the option to receive a preventative mastectomy and reconstructive surgery here, even if it is usually not prescribed.
Argentine insurance plans may cover a portion of the care, but patients should plan for partial self-payment.
Supreme Court Ruling on Gene Patents
After Angelina Jolie’s announcement in 2013, Myriad Genetics (MYGN) saw its stock spike briefly, but the corporate advantage was short-lived.
That same year, the US Supreme Court ruled that naturally occuring human genes cannot be patented, a landmark decision hailed as a win for cancer patients, doctors, and researchers.
While this ruling may gradually reduce the cost of BRCA testing in the U.S., many women still face high out-of-pocket expenses.
This makes Argentina a rare option where high-quality genetic testing is accessible, affordable, and accompanied by expert counseling — an appealing alternative for those uninsured or underinsured in North America.
Make your important health check-up a whole lot more fun by considering a medical vacation to Argentina.
